An interventional study of Telemedicine-Supported Management in Acute Ischemic Stroke, sponsored by Capital Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-03.
Sponsored by Capital Medical University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Ischemic Stroke by Capital Medical University — 20 open to participants now, 25 under way, 10 of them phase 3. Ischemic Stroke · Capital Medical University.
Among the 45 studies in Ischemic Stroke by Capital Medical University, this one has the largest planned enrollment of the 39 interventional ones that give a count, is one of 10 that started in 2026, is one of 14 with no phase, reaches primary completion later than 16 of the 24 other live ones, and was the 37th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →20 of the 45 studies in Ischemic Stroke by Capital Medical University are open now, in 1 country. Recruiting first, the newest first:
Capital Medical University · Sites in China
Ages 18–80
Capital Medical University · Sites in China
Ages 18+
Capital Medical University · Sites in China
Ages 18+
Capital Medical University · Sites in China
Ages 40–80
Capital Medical University · Sites in China
Ages 18–80
By country, each count listing its studies:
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 12 · Phase 3 12
First in 2017; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,400 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 208 across the 39 interventional studies, 550 across the 6 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Capital Medical University is the lead sponsor of 296 studies on the registry; 90 are open to participants now.
11 of the studies in Ischemic Stroke by Capital Medical University that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559241Phase 3Capital Medical UniversityRemote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy(RECAST-MT) | 2026-11 |
| NCT07509645Phase 3Capital Medical UniversityEfficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke | 2027-04-20 |
| NCT07263308Phase 3Capital Medical UniversityAlbumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2 | 2027-06-20 |
| NCT06666764Phase 3Capital Medical UniversityNormobaric Oxygen in AIS Transferred for EVT | 2027-10 |
| NCT07139314Capital Medical UniversityTiming of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation 2 | 2026-11-30 |
Add all 11 to your calendar (.ics) → With an account.
Among the 45 studies in Ischemic Stroke by Capital Medical University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Telemedicine-supported stroke care can provide standardized guidance to hospitals and regions with limited medical resources, thereby improving treatment outcomes for stroke patients in these areas. While this approach has been widely adopted in many developed countries, its efficacy in guiding basic-level hospitals to manage acute ischemic stroke requires further investigation through large-scale, high-quality studies.
This study focused on patients with acute ischemic stroke who sought treatment at basic-level hospitals, aiming to investigate the efficacy and safety of treating acute ischemic stroke with telemedicine-supported management. Hospitals assigned to the experimental group received remote consultation guidance, quality control and professional training from expert teams at leading stroke centers, China National Center for Neurological Disorders. Hospitals in the control group did not receive telemedicine-supported management.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Hospital Inclusion Criteria:
Patient Inclusion Criteria:
Exclusion Criteria:
Hospital Exclusion Criteria:
Patient Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Receive remote guidance from expert stroke centers for treatment of patients with intravenous thrombolysis, along with quality control for standardized workflow support, and professional training.
Other: Telemedicine-Supported Management
Control-group patients will receive routine stroke care at their primary care hospitals, with no remote consultation, study-related quality control, or extra training. Care will follow the hospitals' usual protocols, including emergency assessment, neurological evaluation, imaging, and intravenous thrombolysis. Hospitals may continue their regular stroke-related training during the study to reflect real-world practice.
Receive round-the-clock 7×24h remote consultation guidance from expert teams at leading stroke centers, covering patient triage and initial assessment, thrombolysis decision-making, and treatment guidance. Undergo quality control for standardized workflow implementation, and professional training.
Proportion of patients with mRS scores of 0-1
Time frame: 90 days
Intravenous thrombolysis rate
Time frame: 4.5 hours
mRS score
Ranges from 0 to 6 points, with lower scores indicating better functional outcome.
Time frame: 90 days
Door-to-(thrombolysis)needle-time
The time calculation begins when the patient arrives at the hospital and ends upon receiving thrombolytic therapy. The theoretical range is 0 to 270 minutes.
Time frame: 4.5 hours
Rate of endovascular therapy receipt among eligible patients
Time frame: 24 hours
Proportion of sICH
The time frame is within 36 hours after thrombolysis in patients. Symptomatic intracranial hemorrhage occurring during this period is considered an endpoint event. If the patient is discharged within 36 hours, the endpoint event is observed during the hospitalization period.
Time frame: Within 36 hours of thrombolysis
Proportion of any type of ICH
The time frame is within 36 hours of thrombolysis administration. Any type of intracerebral hemorrhage occurring during this period is considered an endpoint event. If the patient is discharged within 36 hours, the endpoint event is observed during the hospitalization period.
Time frame: Within 36 hours of thrombolysis
All-cause mortality rate
Time frame: 90 days
Started Feb 2026 (actual). Primary completion is estimated for Jun 2027, 16 months after the start.
Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 16 months is below that.
Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.